Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 445

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 3
Chunk 445
---
 ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable
terms, or at all, will be available when needed. If we are unable to raise additional capital and continue to have insufficient funds,
we may be required to cease our operations altogether. The above matters raise substantial doubt regarding our ability to continue as
a going concern.

Cash Flow Summary 

The following table provides a summary of our net
cash flow activity for the years ended December 31, 2024 and 2023:

    Year Ended
                                                                                December 31, 2024  
    Year Ended
                                                                                December 31, 2023 
  
    Net cash used in operating activities 
    $(241,159) 
    $(497,467)
  
    Net cash provided by investing activities 
     –  
     433,000 
  
    Net cash provided by financing activities 
     200,000  
     – 
  
    Net decrease in cash and cash equivalents 
    $(41,159) 
    $(64,467)

Cash Flows From Operating Activities 

Net cash used in operating activities for the year
ended December 31, 2024 consisted of our net loss of $921,983 offset by (i) non-cash interest expense of $73,533, (ii) non-cash share-based
compensation expense of $4,867, (iii) the accretion to redemption value on convertible notes of $1,446, and (iv) a net change in operating
assets and liabilities of $604,215 primarily due to an increase in accrued compensation of $582,741 and accounts payable of $16,387.

Net cash used in operating activities for the year
ended December 31, 2023 consisted of our net loss of $1,008,235 combined with a decrease in the fair value of the derivative liability
of $46,700 and a gain on redemption of preferred stock of Holocom of $433,000, which amounts were offset by (i) non-cash share-based compensation
expense of $21,935, (ii) non-cash interest expense of $73,333, (iii) the accretion to redemption value on convertible notes of $15,842,
and (iv) a net change in operating assets and liabilities of $879,358 primarily due to an increase in accrued compensation, accrued consulting,
and other accrued expenses of $877,067, in aggregate.

 35